AVALIAÇÃO DO USO DO CANABIDIOL EM PACIENTES PORTADORES DE DOENÇA AUTOIMUNE

Abstract

Cannabidiol (CBD), a phytocannabinoid extracted from Cannabis sativa, has emerged as a potential therapeutic alternative for the management of autoimmune diseases due to its anti-inflammatory and immunomodulatory properties without psychoactive effects. This systematic review analyzed 30 studies published over the past 15 years, encompassing experimental models and clinical trials, aiming to synthesize the evidence regarding the efficacy and safety of CBD. Results demonstrated that CBD modulates immune responses, reduces the production of pro-inflammatory cytokines, and alleviates clinical manifestations of diseases such as multiple sclerosis, rheumatoid arthritis, and psoriasis. Clinical trials reported significant improvement in symptoms such as pain, fatigue, and joint stiffness, with adverse events generally mild and well tolerated. However, methodological limitations were observed, including dose heterogeneity and short study durations. It is concluded that CBD represents a promising strategy for the treatment of autoimmune diseases, although larger-scale controlled trials are necessary to consolidate its efficacy and safety profile.